Get instant, interactive modeling on almost 3,000 cancer drugs and affected signaling pathways across close to 90 different cancer types. The Oncology Drug Pathway Analyzer is an interactive high level data tool to analyze several thousand drug-pathway connections in close to 90 different cancer indications on the fly. The tool lets you examine both single pathways and crosstalk between pathways of drugs and filter the included drugs per pathway by twelve drug specific parameters (i.e. Indication, Stage, Company, Molecular function etc.). The Oncology Drug Pathway Analyzer is a great facilitator to realize your position and options in drug development when utilizing pathways and it significantly cuts the amount of time it takes to do so

1. Oncology Drug Pathway Analyzer™
BioSeeker Group AB
May, 2012

2. You Use this Analyzer Tool to:
Map the competition and find suitable benchmarking drugs
based on specific pathways and drug properties
Uncover potential indication expansion areas for your drug
portfolio
Reveal repositioning opportunities for your older, shelved
drugs
Evaluate the progression and success of targeting certain
pathways for the treatment of cancer
Investigate drugs which affect crosstalk between key pathways
Investigate different combination therapy options available to
you in various cancer types. Use this tool to look for the most-
efficient ways to combine your drug with other targeted
agents.
Find possible adjuvant therapy settings with other drugs

3. How you get instant, interactive pathway
modeling on almost 3,000 cancer drugs!
Go from very niched The Analyzer will
pathways to broad process almost
general pathways. The 3,000 drugs which
together have more
Analyzer includes
than 6,200
hundreds of pathways Pathways
developmental
from BioCarta, KEGG Drugs projects in cancer
and Netpath
Oncology
There are 87 Drug Pathway
cancer indications Analyzer™
to cross-reference Indications The near 3,000
with drugs have close
Targets to 700 molecular
targets, linking
them to several
hundred pathways

4. Drugs
Facts: Refine Pathway Modeling by:
• Almost 3,000 (2,820) cancer drugs • Drug Name
• More than 6,200 developmental • Drug Status
projects • Compound Type
• Company
• Drug Development Partners
Cancer Drug Development
Ceased
Suspended
Preclinical
Phase I
Phase II
Phase III
Pre-registration
Registered
Marketed
0 200 400 600 800 1000

5. Targets
Facts: Refine Pathway Modeling by:
• Almost 700 (694) molecular • Target Name
targets, which link the near 3,000 drugs • Molecular Function
to several hundred pathways • Mechanism
• They represent 90 different molecular • Target Localization
functions
• They are found in 41 different subcellular
localizations
Top 5 Molecular Functions Top 5 Target Localizations
Transmembrane receptor protein Endoplasmic reticulum
tyrosine kinase activity
Catalytic activity Extracellular
Protein serine/threonine kinase Nucleus
activity
G-protein coupled receptor Cytoplasm
activity
Receptor activity Plasma membrane
0 20 40 60 80 100 0 50 100 150 200 250 300

6. Cancer
Indications Cancer Indications
Acute Lymphocytic Leukemia
Acute Myelogenous Leukemia
Facts: Adrenal Cancer
• There are 87 cancer indications to
cross-reference with Basal Cell Cancer
B-cell Lymphoma
Refine Pathway Modeling by: Benign prostatic hyperplasia
• Indication Top 5 Included Cancer Indications
Biliary Cancer
• Developmental Stage
• Clinical Status Bladder Cancer
Ovarian Cancer
Bone Cancer
Non-Small Cell Lung Cancer
Brain Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Cancer (general)
Breast Cancer
Carcinoid
0 50 100 150 200 250 300 350 400 450
Carcinoid syndrome
Cervical Cancer

7. Pathways
Facts:
• Go from very niched pathways to broad general pathways. The Analyzer
includes hundreds of pathways from BioCarta, KEGG and Netpath
Netpath (25) EGFR1 Signaling TGF-beta Receptor Signaling
KEGG (205) Focal adhesion ErbB signaling
Jak-STAT signaling MAPK signaling
BioCarta (315) Erk1/Erk2 Mapk Signaling Ras Signaling
EGF Signaling MAPKinase Signaling
AKT Signaling p53 Signaling

8. Real Case Scenario (combination therapy):
 In the March 20, 2012 issue of the journal Cancer Cell, researchers
at The University of Texas MD Anderson Cancer Center reveal that
the mTOR molecular pathway stimulates the activity of the Gli1
protein in the development and progression of esophageal cancer.
Hitherto it is known that the Hedgehog pathway is the established
pathway for activating Gli1.
 In experiments the researchers then went on to show that a
combination of the mTOR inhibitor everolimus (Afinitor) and the
Hedgehog inhibitor vismodegib (Erivedge) steeply reduced the tumor
burden in a mouse model of esophageal adenocarcinoma.
The Analyzer would in seconds:
 Accesses how many and which drug are available for potential drug
combination therapies in affecting both the Hedgehog- and the mTOR
pathway
 Overlay the mTOR pathway with the Hedgehog pathway and then report
which drugs affect both pathways and how
 Allow you to further refine the above two results (using up to twelve different
filter settings), for an example by either limiting the findings to esophageal
cancer and/or only listing approved drugs like everolimus (Afinitor) and
vismodegib (Erivedge)

9. The Oncology Drug Pathway Analyzer
Comes in Two Versions

10. Drug Profile Reports (Premium)
• Dynamic Report Generator
– Single Drug
– Multiple Drugs Matching Your Criteria
• Each Profile Reports on Up to 15
Information Classifications on a Drug:
Name & Synonyms Business & Market Phase III
Company & Partners Target Data Phase II
Drug Description Mechanism Phase I
Compound Data Pathway Preclinical
Patent Data Developmental Projects Licensing
• Estimated 6,200 page report to print
data for all drugs included

11. Start Using the Analyzer Today!
1. It's the only tool of its kind
2. It sits right at your desktop, not in department above you or across the
ocean
3. Once you get it you have it! No subscription
4. So, bring out the power in your pipeline and start to quickly analyze the
impact of emerging pathway data in cancer by getting your own version
of the Oncology Drug Pathway Analyzer.
5. It comes in two versions, Standard and Premium. The additional great
feature of the Premium version is that it also gives you instant access to
almost 3,000 up to date and extensive drug developmental profiles (at
the low price of around 1 EUR/profile).
Price Price
License Type (Standard) (Premium)
Single 6,900 EUR 9,900 EUR
Global 13,800 19,800

12. Thank You